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Abstract
Metal-chelating aminocarboxylic acids are being used in a broad range of domestic prod-
ucts and industrial applications. With the recent identification of the fungal natural product 
aspergillomarasmine A as a potent and selective inhibitor of metallo-β-lactamases and a 
promising codrug candidate to fight antibiotic resistant bacteria, the academic and indus-
trial interest in metal-chelating chiral aminocarboxylic acids further increased. Here, we 
report a biocatalytic route for asymmetric synthesis of aspergillomarasmine A and various 
related aminocarboxylic acids from retrosynthetically designed substrates. This synthetic 
route highlights a highly regio- and stereoselective carbon-nitrogen bond-forming step 
catalyzed by ethylenediamine-N,N’-disuccinic acid lyase. The enzyme shows broad sub-
strate promiscuity, accepting a wide variety of amino acids with terminal amino groups for 
selective addition to fumarate. We also report a two-step chemoenzymatic cascade route for 
the rapid diversification of enzymatically prepared aminocarboxylic acids by N-alkylation 
in one pot. This biocatalytic methodology offers a useful alternative route to difficult ami-
nocarboxylic acid products.
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Aminocarboxylic acids that contain several carboxylate groups bound to one or more 
nitrogen atoms form an important group of chelating agents.1 Their ability to form stable 
complexes with metal ions is the basis for their use in a broad range of domestic prod-
ucts, as well as industrial and medical applications.1-4 An important aminocarboxylic acid 
that recently received considerable attention is the fungal natural product aspergillomar-
asmine A (AMA, 1a, Figure 1a).5-7 It was originally discovered and characterized for its 
plant wilting and necrotic activity by Lederer and coworkers in 1965.8 Later, in the 1980s, 
the molecule was evaluated as an inhibitor against human angiotensin-converting enzyme 
(ACE).9 Recently, AMA has been highlighted as a potent and selective inhibitor of New 
Delhi metallo-β-lactamase-1 (NDM-1) via a zinc-chelation mechanism, with an IC50 value 
at low-micromolar concentration.5 Moreover, AMA could efficiently restore the activity 
of meropenem in a mouse model infected with a lethal dose of NDM-1-expressing Kleb-
siella pneumonia, demonstrating the potential of AMA as a promising co-drug candidate to 
rescue or potentiate β-lactam antibiotics in combination therapies.5
Retrosynthetic analysis of AMA (1a, Figure 1a) suggests the compound can be decon-
structed into three amino acid moieties –– aspartic acid (Asp) and two 2-aminopropionic 
acids (Apa1 and Apa2) –– where the amino acid moieties are connected through C-N bonds 
rather than conventional peptide bonds. The stereochemical assignment (configuration at 
C2, C2’, and C2’’) of natural AMA was reassigned from original incorrectly proposed (2S, 
2’R, 2’’R) to the correct configuration (2S, 2’S, 2’’S) through total synthesis.10,11 Replacing 
the terminal Apa2 moiety of AMA with glycine provides another related natural product, 
aspergillomarasmine B (AMB, 2a, Figure 1a), with (2S, 2’S) absolute configuration.12 Toxin 
A (3a, Figure 1a), a biosynthetic precursor of AMA, is built from two amino acid moieties 
(Asp and Apa) through a C-N bond. The absolute configuration of 3a was first incorrectly 
assigned as (2S, 2’R) in 1979,13 which was later corrected to (2S, 2’S) through chemical syn-
thesis and feeding experiments in 1991.14 
The intriguing structural features and important biological activities of AMA have attracted 
attention from synthetic chemists, culminating in the elegant total synthesis of AMA and 
related compounds (Figure 1a).10-12,15 A modular approach towards AMA via a late-stage 
oxidation strategy (14 steps, 4% yield) was first reported by Lei and coworkers.10 Next to 
that, Wright and coworkers employed o-nosyl aziridine as a key intermediate in the total 
synthesis of AMA (9 steps, 1% yield).11 Since then, an improved route utilizing a sulfamidate 
approach towards AMA has been achieved (6 steps, 19% yield) by Silvia et al.12 However, 
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creating a biocatalytic methodology as alternative route to AMA, AMB and other difficult 
aminocarboxylic acids is an as yet unmet challenge.
The enzyme ethylenediamine-N,N’-disuccinic acid (EDDS) lyase catalyzes an unusual two-
step sequential addition of ethylenediamine (4) to two molecules of fumaric acid (5) pro-
viding (S)-N-(2-aminoethyl)aspartic acid (AEAA, 6) as an intermediate and (S, S)-EDDS 
(7) as the final product (Figure 1b); it also catalyzes the reverse reaction, converting 7 into 
4 and two molecules of 5.16-18 Interestingly, structural comparisons showed that toxin A 
(3a), AMA (1a) and AMB (2a) show striking similarities to the natural EDDS lyase sub-
strates AEAA (6) and EDDS (7). This prompted us to explore EDDS lyase as biocatalyst for 
the asymmetric synthesis of toxin A, AMA, and AMB. 
Here we report a biocatalytic methodology for asymmetric synthesis of toxin A, AMA, AMB 
and related aminocarboxylic acids from retrosynthetically designed substrates. This biocat-
alytic strategy highlights a highly regio- and stereoselective carbon-nitrogen bond-forming 
step catalyzed by EDDS lyase, and offers an alternative synthetic choice to prepare difficult 
aminocarboxylic acid products.
Figure 1. Natural aminocarboxylic acid products. Structural similarities between EDDS lyase 
substrates and natural products AMA, AMB and toxin A. a) Previous total synthesis strategies and 









































Biocatalytic synthesis of toxin A and related compounds 
Inspired by previous studies showing that toxin A (3a, Asp-Apa) is a precursor in the bio-
synthesis of AMA (1a, Asp-Apa1-Apa2),14 we envisioned that 3a could serve as a precious 
building block for the synthesis of more complex aminocarboxylic acids, such as AMA, 
AMB and their derivatives. Structurally, toxin A has only one extra carboxylate group at 
the C2’ position compared with AEAA (6), which is the intermediate product formed in 
the natural EDDS lyase-catalyzed two-step addition reaction (Figure 1). This prompted 
us to start our investigations by testing (S)-2,3-diaminopropionic acid (8a, Table 1) as an 
unnatural substrate in the EDDS lyase-catalyzed amination of fumarate (5). Remarkably, 
the enzymatic amination reaction occurred exclusively at the less-sterically hindered ter-
minal 3-amino group of 8a while the 2-amino group of 8a remained untouched, providing 
3a as a single product. Notably, no further addition of the 2’-amino group of product 3a to 
fumarate was observed. Under optimized conditions, excellent conversion (98%) and good 
isolated yield (52%) of 3a were achieved using only 0.05 mol% biocatalyst loading (Table 1). 
Product 3a was identified as the desired (2S, 2’S)-diastereomer (de >98%, Table 1), with the 
(2S)-stereogenic center being set by EDDS lyase and the (2’S)-stereogenic center derived 
from starting substrate 8a. Interestingly, the (R)-enantiomer of 2,3-diaminopropionic acid 
(8b) was also accepted as substrate by EDDS lyase, giving (2S, 2’R)-3b as the anticipated 
diastereomeric product with excellent conversion (97%) and stereoselectivity (de >98%), 
and high isolated yield (82%, Table 1).
Substrates with longer chains, including (S)-2,4-diaminobutyric acid (8c), (S)-2,5-diamino 
pentanoic acid (ornithine, 8d) and (S)-2,6-diaminohexanoic acid (lysine, 8e), were also 
well accepted by EDDS lyase, yielding the respective products 3c-e. High conversions (94-
96%), good isolated product yields (55-75%), and excellent regio- and stereoselectivity (de 
>98%) were observed (Table 1). As anticipated, only the less sterically hindered terminal 
amino groups of 8c-e functioned as the nucleophile in the enzymatic additions to fumarate. 
In comparison to the previously reported four-step chemical synthesis of (2S, 2’S)-toxin 
A (3a)12 and the four-step chemical synthesis of (2S, 3’S)-3c (see Supplementary Informa-
tion), our biocatalytic methodology highlights a high-yielding one-step enzymatic synthe-
sis of toxin A (3a) and its homologs 3c-e with excellent regio- and stereoselectivities.
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1 8a 3a 98 (52) >98 (2S,2’S)e
2 8b 3b 97 (82) >98 (2S,2’R)e
3 8c 3c 96 (75) >98 (2S,3’S)f
4 8d 3d 94 (72) >98 (2S,4’S)g
5 8e 3e 95 (55) >98 (2S,5’S)g
6 8f 3f 91 (34) >99 (S)h
7 8g 3g 92 (37) >99 (S)h
8 8h 3h 92 (53) >99 (S)i
aConditions and reagents: fumaric acid (5, 10 mM), substrates 8a-h (100 mM) and EDDS lyase (0.05 mol% based on fumaric acid) in buffer (20 mM 
NaH2PO4/NaOH, pH 8.5), rt, 24 h (8f, 48 h). The amount of applied purified enzyme was chosen such that reactions were completed within 24-48 
h. bConversions were determined by comparing 1H NMR signals of substrates and corresponding products. cIsolated yield after ion-exchange chroma-
tography. dDiastereomeric excess (de) for 3a-e was determined by 1H NMR (Figures S2-S5); whereas enantiomeric excess (ee) for 3f-h was determined 
by HPLC on a chiral stationary phase using authentic standards (Figures S10-S12). eThe absolute configurations of 3a and 3b were determined by 
referring to the literature.14 fThe absolute configuration of 3c was assigned by 1H NMR spectroscopy using an authentic standard and diastereomeric 
mixture with known (2S, 3’S) and (2S/R, 3’S) configurations, respectively (Figure S3). gThe purified products 3d and 3e could be tentatively assigned 
the (S, S)-configuration on the basis of analogy. hThe absolute configurations of 3f and 3g were determined by chiral HPLC using authentic standards 
with known R or S configuration. iThe absolute configuration of 3h could be tentatively assigned by optical rotation on the basis of comparison to the 







































Substrates with only one terminal NH2 group, such as glycine (8f), β-alanine (8g), and 
γ-aminobutyric acid (8h) were also well accepted by EDDS lyase, giving excellent conver-
sions (91-92%) and yielding the corresponding aminocarboxylic acids 3f-h as the (S)-con-
figured enantiomers with >99% ee (Table 1). Notably, while the α-amino acid glycine (8f) 
was accepted as substrate by EDDS lyase, other tested α-amino acids with substituents at 
the Cα-position failed to give corresponding products (see Supplementary Information), 
indicating that the steric environment of the nucleophilic amino group is essential for sub-
strate conversion by EDDS lyase. It is also noteworthy that product 3f (aspartic-N-mon-
oacetic acid, ASMA) was shown to be an efficient tricarbonyl ligand in the formation of 
99mTc(CO)3(ASMA) and Re(CO)3(ASMA) complexes as renal (radio)tracers.19,20 Hence, our 
biocatalytic approach provides a convenient method to prepare such tricarbonyl ligands in 
optically pure form, which could be used for further development of (radio)tracers.
Two-step chemoenzymatic synthesis of AMB and its homologs
Previous studies11,12 have confirmed that the primary amino group (2’-NH2) in the Apa 
moiety of toxin A (3a) is much more reactive than the secondary amino group (2-NH) in the 
Asp moiety, providing an opportunity for regioselective N-alkylation at the 2’-NH2 position 
of 3a. Encouraged by the exquisite EDDS lyase-catalyzed biotransformation providing 3a 
and its derivatives with excellent conversions and stereoselectivities, we set out to combine 
the biotransformation and chemical N-alkylation in one pot to prepare more complex mol-
ecules, including the important metallo-β-lactamase inhibitor AMB (2a) and its homologs 
(Figure 2). To effect the second N-alkylation step in the one-pot synthesis of 2a, the first 
requirement was complete consumption of the starting amine substrate 8a in the first enzy-
matic step to prevent it from reacting (and lowering the desired product yield) during the 
subsequent chemical N-alkylation step. Therefore, the enzymatic step was modified using 
a 3-fold excess of fumarate (rather than an excess of amine) to drive 8a to completion. 
Remarkably, excellent conversion (98% after 24 h) of substrate 8a was achieved providing 
(2S, 2’S)-3a as a single enzymatic product. Without any purification, (2S, 2’S)-3a was sub-
jected to N-alkylation using bromoacetic acid in the same pot, of which the pH was adjusted 
and maintained at 11 for 6 h at 70 °C, providing high conversion (84%) for the second step. 
Comparison of 1H NMR and 2D 1H-1H COSY NMR spectra of product 2a (23% isolated 
yield) with those of (2S, 2’S)-3a showed that the N-alkylation had unambiguously occurred 
at the 2’-NH2 position of 3a, demonstrating that product 2a has the desired Asp-Apa-Gly 
structure (Figures S6-S9). With both stereogenic centers being derived from intermediate 
(2S, 2’S)-3a, product 2a has the correct (2S, 2’S)-configuration.
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To further demonstrate the synthetic usefulness of this one-pot strategy, we successfully 
modified the third Gly moiety or the second Apa moiety of AMB by either replacing the 
alkylation agent (3-bromopropanoic acid) or the starting substrate (8c) in the chemoenzy-
matic cascade, yielding AMB homologs (2S, 2’S)-2b or (2S, 3’S)-2c, respectively (Figure 2). 
Note that the stereogenic centers of 2b and 2c have been derived from the respective inter-
mediates 3a and 3c, of which the absolute configurations have been unambiguously estab-
lished (Table 1).
Figure 2. One-pot two-step chemoenzymatic synthesis of AMB and its homologs. Reagents and 
reaction conditions: a) substrate (8a or 8c, 1 eq.), fumaric acid (3 eq.) and EDDS lyase (0.05 mol% 
based on 8a or 8c) in buffer (20 mM NaH2PO4/NaOH, pH 8.5), rt, 24 h. b) bromoacetic acid, pH 11 at 
70 °C for 6 h. c) 3-bromopropanoic acid, pH 11 at 70 °C for 6 h. Conversions are shown as percentage 
values.
Enzymatic synthesis of AMA, AMB and related compounds
The one-pot chemoenzymatic cascade described above provides a rapid route to synthesize 
(2S, 2’S)-AMB (2a) and its homologs. With the aim of developing a convenient synthetic 
methodology for (2S, 2’S, 2’’S)-AMA (1a), we envisioned a retrosynthesis of 1a by incorpo-
rating an EDDS lyase-catalyzed amination step (Figure 3). This stereoselective disconnec-
tion of the C-N bond would result in (2S, 2’S)-9d as a challenging starting substrate for the 
EDDS lyase-catalyzed amination reaction. Similar retrosynthesis could be applied to 2a, 







































Figure 3. Retrosynthesis of AMA and AMB. Biocatalytic retrosynthesis suggests that AMA and AMB 
can be prepared via EDDS lyase catalyzed enantioselective amine addition to fumarate.
Considering that compound (S)-9a is structurally less bulky than (2S, 2’S)-9d, which may 
indicate a better chance of acceptance by the enzyme, we first prepared and tested (S)-9a as 
a retrosynthetically designed substrate for EDDS lyase. Remarkably, using a 4-fold excess of 
fumarate over (S)-9a, and only 0.05 mol% biocatalyst loading in 20 mM sodium phosphate 
buffer (pH 8.5) at room temperature, (S)-9a was readily converted by EDDS lyase to afford 
a single product 2a with 80% conversion and 47% isolated yield (Table 2). The enzymatic 
product 2a was identified as the desired (2S, 2’S)-diastereomer of AMB (de >98%, Table 2), 
with the (2S)-stereogenic center being set by EDDS lyase and the (2’S)-stereogenic center 
derived from starting substrate (S)-9a. 
To tackle our original target AMA (1a), retrosynthetically designed substrate (2S, 2’S)-9d 
was prepared via a β-lactone approach (see Supplementary Information). To our delight, 
EDDS lyase accepted (2S, 2’S)-9d as substrate in the amination of fumarate to give prod-
uct 1a under the same reaction conditions that were used for conversion of substrate (S)-
9a, although low conversion (30%) was observed. We optimized the reaction conditions 
and found that 0.15 mol% of biocatalyst loading in 50 mM NaHCO3/Na2CO3 buffer at pH 
9.0 and 37 °C afforded product 1a with good conversion (79% in 48 h) and in 26% iso-
lated yield. A comparison of the 1H NMR spectrum of enzymatic product 1a with those 
reported for (2S, 2’S, 2’’S)-AMA (Table S1) and (2R, 2’S, 2’’S)-AMA confirmed that product 
1a had the desired (2S, 2’S, 2’’S)-configuration (de >98%, Table 2), with two stereogenic 
centers derived from the starting substrate (2S, 2’S)-9d and the other one set by the enzyme. 
In addition, small amounts of the cyclic anhydro-AMA were obtained during purification.
With the aim to further explore the substrate promiscuity and synthetic capability of EDDS 
lyase, we prepared and analyzed compounds 9b, 9c, and 9e as substrates in the enzymatic 
amination of fumarate. The corresponding AMA homolog 1b and AMB homologs 2b and 
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2c were obtained with good conversions (65-71%), excellent stereoselectivities (de >98%), 
and in 20-46% isolated yield (Table 2).
Table 2. Enzymatic synthesis of AMA, AMB and their homologs.










80 (47) >98 (2S,2’S)g
2b 9b 2b 71 (46) >98 (2S,2’S)g




79 (26) >98 (2S,2’S,2’’S)h
5b 9e 1b 65 (20) >98 (2S,3’S,2’’S)i
aSubstrate 9a (1 eq.), fumaric acid (4 eq.) and EDDS lyase (0.05 mol% based on 9a) in buffer (20 mM NaH2PO4/NaOH, pH 8.5), rt, 24 h. 
bSubstrate 9b, 9c and 9e (1 eq.), fumaric acid (4 eq.) and EDDS lyase (0.15 mol% based on 9b, 9c and 9e) in buffer (50 mM Tris/HCl, pH 9.0), 
37 °C, 48 h; cSubstrate 9d (1 eq.), fumaric acid (4 eq.) and EDDS lyase (0.15 mol% based on 9d) in buffer (50 mM NaHCO3/Na2CO3, pH 
9.0), 37 °C, 48 h. dConversions were determined by 1H NMR. eIsolated yield after ion-exchange chromatography. No formation of side products 
has been observed and isolated yields of the desired products may be further improved by optimizing the purification protocols. fDiastereomeric 
excess (de) was determined by 1H NMR. gThe absolute configurations of 2a-c were assigned by 1H NMR spectroscopy using chemoenzymatically 
synthesized authentic standards 2a-c with known (S, S)-configuration. hAbsolute configuration of 1a was determined by referring to the literature 
(Table S1).5,12 iProduct 1b could be tentatively assigned the (2S, 3’S, 2’’S)-configuration on the basis of analogy.
Discussion
Using a biocatalytic retrosynthesis approach,21-23 we have successfully demonstrated that 
EDDS lyase can be applied as biocatalyst for the asymmetric synthesis of the natural prod-
ucts toxin A, AMA and AMB, as well as related chiral aminocarboxylic acids. This enzyme 
shows remarkably broad substrate promiscuity, and excellent regio- and stereoselectivity, 
allowing the selective addition of a wide variety of amino acids to fumarate. Only less ster-
ically hindered terminal amino groups of the starting substrates functioned as the nucleo-
phile in the enzymatic additions, providing insight into the regioselectivity of this enzyme. 







































of enzymatically prepared aminocarboxylic acids by N-alkylation in one pot. Our (chemo)
enzymatic methodology offers a useful alternative route to difficult aminocarboxylic acid 
products, as exemplified by the synthesis of the natural products toxin A (1 step, 52% yield), 
AMA (4 steps, 10% yield), and AMB (one-pot, 2 steps, 22% yield). The isolated product 
yields are comparable to those of previously reported chemical synthesis strategies for toxin 
A (4 steps, 46% yield), AMA (6-14 steps, 1-19% yield) and AMB (5-6 steps, 8-10% yield).10-12
In addition to EDDS lyase, several other enzymes have previously been characterized that 
catalyze the asymmetric addition of substituted amines to fumarate or its derivatives. These 
include aspartate ammonia-lyases, methylaspartate ammonia-lyases, argininosuccinate 
lyases and adenylosuccinate lyases.17,18,24,25 With the notable exception of an engineered var-
iant of methylaspartate ammonia lyase, which accepts various alkylamines as non-natural 
substrates,26 these enzymes have a rather narrow nucleophile scope. In contrast, EDDS lyase 
has a very broad nucleophile scope, accepting a wide variety of structurally diverse amino 
acids, allowing the biocatalytic preparation of numerous valuable aminocarboxylic acids. 
As such, EDDS lyase nicely complements the rapidly expanding toolbox of enzymes for 
asymmetric synthesis of unnatural amino acids.24
We have initiated studies aimed at further exploring novel substrates (e.g. unsaturated 
mono- and dicarboxylic acids, including fumarate derivatives) for EDDS lyase to find new 
promiscuous reactions. In addition, work is in progress to determine crystal structures 
of EDDS lyase, both uncomplexed and in complex with substrates and products, and the 
results will be reported in due course. Such structures could guide the engineering of EDDS 
lyase to enhance its catalytic activity (allowing lower catalyst loadings) and further expand 
its unnatural substrate scope.
Methods
Enzyme expression and purification
Escherichia coli TOP10 cells containing the pBADN (EDDS lyase-His) plasmid were col-
lected from a Luria-Bertani (LB) agar plate, containing 100 μg/mL ampicillin (Ap) and used 
to inoculate LB/Ap medium (10 mL). After overnight incubation at 37°C, the culture was 
used to inoculate fresh LB/Ap medium (1 L). The cells were grown at 37°C for about 
4 h, until the OD600 reached 0.8-1.0. Arabinose (0.05 %, w/v) was added to induce enzyme 
expression. Cultures were incubated at 20 °C for 18 h with vigorous shaking. Cells were 
harvested by centrifugation and stored at –20 °C until further use. 
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In a typical purification experiment, 4 g of wet cells (from 1 L culture) were suspended 
in lysis buffer (15 mL, 50 mM Tris-HCl, 300 mM NaCl, 20 mM imidazole, pH 8.0). Cells 
were disrupted by sonication for 4 x 40 s (with 5 min interval between each cycle) at a 
60 W output. The unbroken cells and debris were removed by centrifugation. The superna-
tant was filtered through a filter (pore diameter 0.45 μm) and incubated with Ni sepharose 
resin (1 mL slurry in a small column at 4 °C for 18 h), which had previously been equil-
ibrated with lysis buffer. The unbound proteins were eluted from the column by gravity 
flow. The column was first washed with lysis buffer (15 mL) and then with buffer A (30 mL, 
50 mM Tris-HCl, 300 mM NaCl, 30 mM imidazole pH 8.0). Retained proteins were eluted 
with buffer B (5 mL, 50 mM Tris-HCl, 300 mM NaCl, 500 mM imidazole pH 8.0). Fractions 
were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
on gels containing acrylamide (4–12%). Fractions containing EDDS lyase were combined 
and loaded onto a HiLoad 16/600 Superdex 200 pg column, which was previously equil-
ibrated with buffer C (180 mL, 20 mM NaH2PO4-NaOH buffer, pH 8.5). The column was 
eluted with buffer C at 1 mL/min for 1.2 column volumes. Fractions were collected and 
analyzed by SDS-PAGE on gels containing acrylamide (4%–12%). The purified enzyme was 
stored at –20 °C until further use (Figure S1).
Biotransformations and purification of toxin A and related 
compounds
Reaction mixtures (15 mL) consisted of fumaric acid (0.2 mmol) and amines 8a-h (2 mmol) 
prepared in 20 mM NaH2PO4-NaOH buffer, the pH of the reaction mixture was adjusted 
to 8.5. The enzymatic reaction was started by addition of freshly purified EDDS lyase 
(0.05 mol%) and the final volume of the reaction mixture was adjusted immediately to 
20 mL with the same buffer. The reaction mixture was then incubated at room temperature 
for 24 h (48 h for 8f). After completion of the reaction, it was stopped by heating to 70 °C 
for 10 min. The reaction progress was monitored by 1H NMR spectroscopy by comparing 
signals of substrates and corresponding products.
The enzymatic products were purified by two steps of ion-exchange chromatography. 
For a typical purification procedure, the precipitated enzyme was removed by filtration 
(diameter 0.45 μm). The filtrate was loaded slowly onto an anion-exchange column (5 g 
of AG 1-X8 resin, acetate form, 100-200 mesh), which was pretreated with 5 column vol-
umes of 1 M acetic acid (aqueous solution) and then water (until the pH was near neu-
tral). The column was washed with water (3 column volumes) and then 0.1 M acetic acid 
(3 column volumes) until all the excess substrates 8a-h were removed. The products were 







































were collected and loaded onto a cation-exchange column (5 g of Dowex 50W X8 resin, 
100-200 mesh), which was pretreated with 2 M aqueous ammonia (5 column volumes), 
1 M HCl (3 column volumes) and water (5 column volumes). After product loading, the 
column was washed with water (3 column volumes) to remove the remaining fumaric acid 
and subsequently eluted with 2 M aqueous ammonia until the desired product was col-
lected. The ninhydrin-positive fractions were collected, concentrated under vacuum and 
lyophilized to provide the desired products as ammonium salts, which were characterized 
by 1H NMR, 13C NMR and HRMS.
Detailed experimental procedures
For detailed experimental procedures and characterization of compounds, see supplemen-
tary information. All data are available from the corresponding author upon reasonable 
request. Correspondence and requests for materials should be addressed to G.J.P.
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Fumaric acid, L-ornithine, L-lysine, glycine, β-alanine, and γ-aminobutyric acid were 
purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). The compounds (S)-2,3- 
diaminopropionic acid hydrochloride, (R)-2,3-diaminopropionic acid hydrochloride, 
and (S)-2,4-diaminobutyric acid dihydrochloride were purchased from TCI Europe 
N.V. (S)-2-Amino-3-[(tert-butoxycarbonyl)amino] propionic acid, (S)-methyl 2-ami-
no-3-[(tert-butoxycarbonyl)amino]propanoate and Boc-L-serine-β-lactone were purchased 
from Fluorochem Co. (UK). Solvents were purchased from Biosolve (Valkenswaard, The 
Netherlands) or Sigma-Aldrich Chemical Co. Ingredients for buffers and media were 
obtained from Duchefa Biochemie (Haarlem, The Netherlands) or Merck (Darmstadt, Ger-
many). Dowex 50W X8 resin (100-200 mesh) was purchased from Sigma-Aldrich Chemi-
cal Co., and AG 1X8 resin (acetate form, 100-200 mesh) was purchased from Bio-Rad Lab-
oratories, Inc. Ni sepharose 6 fast flow resin and HiLoad 16/600 Superdex 200 pg column 
were purchased from GE Healthcare Bio-Sciences AB (Uppsala, Sweden). Proteins were 
analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under 
denaturing conditions on precast gels (NuPAGE™ 4–12% Bis-Tris protein gels). The gels 
were stained with Coomassie brilliant blue. High performance liquid chromatography 
(HPLC) was performed with a Shimadzu LC-10AT HPLC with a Shimadzu SPD-M10A 
diode array detector. NMR analysis was performed on a Brucker 500 MHz machine at the 
Drug Design laboratory of the University of Groningen. Chemical shifts (δ) are reported 
in parts per million (ppm). Optical rotations were measured on a Schmidt+Haensch Polar-
tronic MH8 polarimeter with a 10 cm cell (c given in g/100 mL). Electrospray ionization 
orbitrap high resolution mass spectrometry (HRMS) was performed by the Mass Spec-
trometry core facility of the University of Groningen.
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II)  Detailed experimental procedures
1. Enzyme expression and purification
The gene encoding EDDS lyase (GenBank: ABG61966) was codon-optimized and synthe-
sized by Eurofins MWG Operon (Ebersberg, Germany), after which it was cloned (using 
NdeI/HindIII sites) into the pBADN-Myc-His expression vector yielding plasmid pBADN 
(EDDS lyase-His). E. coli TOP10 cells containing the pBADN (EDDS lyase-His) plasmid 
were collected from a LB/Ap plate, and used to inoculate LB/Ap medium (10 mL). After 
overnight incubation at 37°C, the culture was used to inoculate fresh LB/Ap medium (1 L). 
The cells were grown at 37°C for about 4 h until OD600 reached 0.8~1.0. Arabinose (0.05%, 
w/v) was added to induce the enzyme expression. Cultures were grown for 18 h at 20 °C 
with vigorous shaking. Cells were harvested by centrifugation and stored at -20 °C until 
further use.
In a typical purification experiment, 4 g of wet cells (from 1 L culture) were suspended in 
lysis buffer (15 mL, 50 mM Tris-HCl, 300 mM NaCl, 20 mM imidazole, pH 8.0). Cells were 
disrupted by sonication for 4 x 40 s (with 5 min interval between each cycle) at a 60 W 
output. The unbroken cells and debris were removed by centrifugation. The supernatant 
was filtered through a pore filter (diameter 0.45 μm), and incubated with Ni sepharose 
resin (1 mL slurry in a small column at 4 °C for 18 h), which had previously been equil-
ibrated with lysis buffer. The unbound proteins were eluted from the column by gravity 
flow. The column was first washed with lysis buffer (15 mL) and then with buffer A (30 mL, 
50 mM Tris-HCl, 300 mM NaCl, 30 mM imidazole pH 8.0). Retained proteins were eluted 
with buffer B (5 mL, 50 mM Tris-HCl, 300 mM NaCl, 500 mM imidazole pH 8.0). Fractions 
were analyzed by SDS-PAGE on gels containing acrylamide (4–12%).
Fractions containing EDDS lyase were combined and loaded onto a HiLoad 16/600 Super-
dex 200 pg column, which was previously equilibrated with buffer C (180 mL, 20 mM 
NaH2PO4-NaOH buffer, pH 8.5). The column was eluted with buffer C at 1 mL/min for 
1.2 column volumes. Fractions were collected and analyzed by SDS-PAGE on gels contain-







































Figure S1. Purifi cation of EDDS lyase by Ni-affi  nity chromatography. Lane 1: PageRulerTM prestained 
protein ladder (Th ermo Scientifi c). Lane 2: unbound protein in fl ow-through fractions. Lane 3: 
fractions from washing step with lysis buff er. Lane 4: fractions from washing step with buff er A. Lane 
5: fractions from elution step with buff er B. Th e molecular weight of EDDS lyase is about 56 kDa 
(including His-tag).
2. General procedure for synthesis of toxin A and its analogues 
General procedure: Th e initial reaction mixture (15 mL) consisted of fumaric acid 
(0.2 mmol) and an amine substrate (8a-8h, 2 mmol) in 20 mM NaH2PO4-NaOH buff er (pH 
8.5), and the pH of the reaction mixture was adjusted to pH 8.5. Th e enzymatic reaction 
was started by addition of freshly purifi ed EDDS lyase (0.05 mol%), and the fi nal volume of 
the reaction mixture was adjusted immediately to 20 mL with the same buff er. Th e reaction 
mixture was then incubated at room temperature for 24 h (48 h for 8f). Aft er completion 
of the reaction, the enzyme was inactivated by heating to 70 °C for 10 min. Th e progress of 
the enzymatic reaction was monitored by 1H NMR spectroscopy by comparing signals of 
substrates and corresponding products. 
Th e products were purifi ed by two steps of ion-exchange chromatography. For a typical 
purifi cation procedure, the precipitated enzyme was removed by fi ltration (pore diame-
ter 0.45 μm). Th e fi ltrate was loaded slowly onto an anion-exchange column (5 g of AG 
1-X8 resin, acetate form, 100-200 mesh), which was pretreated with 5 column volumes of 
1 M acetic acid aqueous solution and then water (until pH was neutral). Th e column was 
washed with water (3 column volumes) and then 0.1 M acetic acid (3 column volumes) until 
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all the excess starting amine substrate was washed out. The products were eluted with 2 M 
acetic acid for 3a-3e or 1 M HCl for 3f-3h. The ninhydrin-positive fractions were collected 
and loaded onto a cation-exchange column (5 g of Dowex 50W X8 resin, 100-200 mesh), 
which was pretreated with 2 M aqueous ammonia (5 column volumes), 1 M HCl (3 column 
volumes) and water (5 column volumes). The column was washed with water (3 column 
volumes) to remove the remaining fumaric acid and eluted with 2 M aqueous ammonia 
until the desired product was collected. The ninhydrin-positive fractions were collected, 
concentrated under vacuum and lyophilized to provide the desired products as ammonium 
salts.
(2S)-N-[(2’S)-2’-amino-2’-carboxyethyl]aspartic acid (3a) 
White solid. 23 mg (52% yield, de >98%). 1H NMR (500 MHz, D2O): δ 
4.09 (t, J = 7.0 Hz, 1H), 3.87 – 3.85 (m, 1H), 3.50 (d, J = 7.5 Hz, 2H), 
2.84 (dd, J = 17.5, 2.7 Hz, 1H), 2.69 (dd, J = 17.5, 9.3 Hz, 1H); 13C NMR 
(126 MHz, D2O): δ 177.2, 173.1, 171.1, 60.2, 50.0, 45.6, 35.7. HRMS (ESI+): calcd. 
for C7H13O6N2, 221.0768 [M+H]+: found: 221.0770. 
In order to determine the absolute configuration of 3a, a 1H NMR spectrum of the lyophilized 
product was recorded with 0.2 M NaOD/D2O as the solvent. 1H NMR (500 MHz, 0.2 M 
NaOD/D2O): δ 3.35 (dd, J = 8.7, 5.2 Hz, 1H), 3.31 (dd, J = 8.8, 4.2 Hz, 1H), 2.71 (dd, J = 
11.9, 4.2 Hz, 1H), 2.53 (dd, J = 11.9, 8.8 Hz, 1H), 2.47 (dd, J = 15.1, 5.2 Hz, 1H), 2.27 (dd, J 
= 15.0, 8.7 Hz, 1H). The 1H NMR spectrum of 3a was matched with reported 1H NMR data 
of LL-toxin A (SS-toxin A)1, which indicated that the absolute configuration of 3a was (2S, 
2’S). The de of product 3a was determined to be >98% by comparison of the 1H NMR data 
of 3a with that of 3b (Figure S2).
(2S)-N-[(2’R)-2’-amino-2’-carboxyethyl]aspartic acid (3b)
White solid. 36 mg (82% yield, de >98%). 1H NMR (500 MHz, D2O): δ 
4.12 (t, J = 7.0 Hz, 1H), 3.90 (dd, J = 8.0, 3.9 Hz, 1H), 3.55 (d, J = 
6.9 Hz, 2H), 2.87 (dd, J = 17.7, 3.9 Hz, 1H), 2.76 (dd, J = 17.7, 8.1 Hz, 
1H); 13C NMR (126 MHz, D2O): δ 177.4, 173.6, 171.3, 60.2, 50.3, 45.9, 35.8. HRMS (ESI+): 
calcd. for C7H13O6N2 [M+H]+: 221.0768, found: 221.0766. 
In order to determine the absolute configuration 3b, a 1H NMR spectrum of the lyophilized 
product was recorded with 0.2 M NaOD/D2O as the solvent. 1H NMR (500 MHz, 0.2 M 
NaOD/D2O): δ 3.37 (dd, J = 8.7, 5.1 Hz, 1H), 3.30 (dd, J = 8.0, 4.8 Hz, 1H), 2.81 (dd, J = 11.9, 
4.8 Hz, 1H), 2.54 – 2.49 (m, 2H), 2.31 (dd, J = 15.1, 8.7 Hz, 1H). The 1H NMR spectrum of 







































that the absolute configuration of 3b was (2S, 2’R). The de of product 3b was determined to 
be >98% by comparison of the 1H NMR data of 3b with that of 3a (Figure S2). 
(2S)-N-[(3’S)-3’-amino-3’-carboxypropyl]aspartic acid (3c)
White solid. 35 mg (75% yield, de >98%). 1H NMR (500 MHz, D2O): 
δ 3.86 – 3.83 (m, 2H), 3.34 – 3.24 (m, 2H), 2.84 (dd, J = 17.6, 4.0 Hz, 
1H), 2.73 (dd, J = 17.6, 7.8 Hz, 1H), 2.35 – 2.20 (m, 2H); 13C NMR 
(126 MHz, D2O): δ 176.8, 173.2, 173.1, 59.5, 52.5, 43.7, 35.6, 27.2. HRMS(ESI+): calcd. 
for C8H15O6N2 [M+H]+: 235.0925, found: 235.0923. The absolute configuration and de was 
determined by comparison of the 1H NMR data of 3c with the 1H NMR data of a chemically 
prepared authentic standard and diastereomeric mixture (Figure S3).
(2S)-N-[(4’S)-4’-amino-4’-carboxybutyl]aspartic acid (3d)
White solid. 36 mg (72% yield, de >98%). 1H NMR (500 MHz, 
D2O): δ 3.81 (dd, J = 8.7, 3.9 Hz, 1H), 3.77 (t, J = 5.9 Hz, 1H), 
3.18 – 3.10 (m, 2H), 2.81 (dd, J = 17.5, 3.9 Hz, 1H), 2.67 (dd, J = 
17.5, 8.7 Hz, 1H), 1.99 – 1.79 (m, 4H); 13C NMR (126 MHz, D2O): δ 177.3, 174.0, 173.1, 
59.5, 54.0, 45.8, 35.5, 27.4, 21.8. HRMS (ESI+): calcd. for C9H17O6N2 [M+H]+: 249.1081, 
found: 249.1079. The de was determined by comparison of the 1H NMR data of 3d with the 
1H NMR data of a chemically prepared diastereomeric mixture (Figure S4).
(2S)-N-[(5’S)-5’-amino-5’-carboxypentyl]aspartic acid (3e)
White solid. 29 mg (55% yield, de >98%). 1H NMR (500 MHz, 
D2O): δ 3.80 (dd, J = 8.7, 3.9 Hz, 1H), 3.74 (dd, J = 6.9, 5.4 Hz, 
1H), 3.15 – 3.05 (m, 2H), 2.81 (dd, J = 17.6, 3.9 Hz, 1H), 
2.67 (dd, J = 17.6, 8.7 Hz, 1H), 1.94 – 1.85 (m, 2H), 1.78 (p, J = 7.6 Hz, 2H), 1.53 – 1.39 (m, 
2H); 13C NMR (126 MHz, D2O): δ 177.1, 174.6, 173.2, 59.3, 54.4, 46.1, 35.4, 29.8, 25.3, 21.5. 
HRMS (ESI+): calcd. for C10H19O6N2 [M+H]+: 263.1238, found: 263.1237. The de was deter-
mined by comparison of the 1H NMR data of 3e with the 1H NMR data of a chemically 
prepared diastereomeric mixture (Figure S5).
(2S)-N-(carboxymethyl)aspartic acid (3f)
White solid. 13 mg (34% yield, ee >99%). 1H NMR (500 MHz, D2O): δ 
3.84 (dd, J = 7.3, 4.3 Hz, 1H), 3.70 (d, J = 16.1 Hz, 1H), 3.62 (d, J = 
16.1 Hz, 1H), 2.85 (dd, J = 17.6, 4.3 Hz, 1H), 2.78 (dd, J = 17.6, 7.4 Hz, 
1H); 13C NMR (126 MHz, D2O): δ 176.9, 173.1, 171.5, 59.1, 48.2, 35.0. HRMS (ESI+): calcd. 
for C6H10O6N [M+H]+: 192.0503, found: 192.0502. The 1H NMR data of 3f is in agreement 
with literature data.2 Chiral HPLC conditions: Chirex 3126-D-penicillamine column 
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(250 mm x 4.6 mm, Phenomenex). Phase A: 2.0 mM CuSO4 aqueous solution, phase B: 
isopropanol, A/B = 95:5 (v/v). Flow rate 1.0 mL/min, 25 °C, UV detection at 254 nm, tR = 
2.4 min. The ee was determined to be >99% by chiral HPLC analysis using authentic stand-
ards with known S or R configuration (Figure S10).
(2S)-N-(2’-carboxyethyl)aspartic acid (3g)
White solid. 15 mg (37% yield, ee >99%). 1H NMR (500 MHz, D2O): 
δ 3.81 (dd, J = 8.0, 4.0 Hz, 1H), 3.26 (t, J = 6.4 Hz, 2H), 2.85 (dd, J = 
17.7, 4.0 Hz, 1H), 2.75 (dd, J = 17.7, 8.1 Hz, 1H), 2.66 (t, J = 6.4 Hz, 
2H); 13C NMR (126 MHz, D2O): δ 177.4, 176.7, 173.1, 59.3, 43.3, 35.1, 32.0. HRMS (ESI+): 
calcd. for C7H12O6N [M+H]+: 206.0659, found: 206.0658. [α]D20 = −10.7 (c 0.36, 0.1 N NH3/
H2O). Chiral HPLC conditions: Chirex 3126-D-penicillamine column (250 mm x 4.6 mm, 
Phenomenex) with 2.0 mM aqueous CuSO4 as mobile phase at a flow rate of 0.8 mL/min, 
20 °C, UV detection at 254 nm, tR = 8.0 min. The ee was determined to be >99% by chiral 
HPLC analysis using authentic standards with known S or R configuration (Figure S11).
(2S)-N-(3’-carboxypropyl)aspartic acid (3h)
White solid. 23 mg (53% yield, ee >99%). 1H NMR (500 MHz, 
D2O): δ 3.78 (dd, J = 7.9, 4.0 Hz, 1H), 3.12 – 3.03 (m, 2H), 2.79 (dd, 
J = 17.3, 3.7 Hz, 1H), 2.67 (dd, J = 17.5, 8.0 Hz, 1H), 2.31 (t, J = 
7.3 Hz, 2H), 1.93 (p, J = 7.3 Hz, 2H); 13C NMR (126 MHz, D2O): δ 180.6, 177.1, 173.3, 59.3, 
46.3, 35.5, 33.7, 22.3. HRMS (ESI+): calcd. for C8H14O6N [M+H]+: 220.0816, found: 220.0814. 
[α]D20 = −9.8 (c 0.32, 0.1 N NH3/H2O). Chiral HPLC conditions: Chirex 3126-D-penicil-
lamine column (250 mm x 4.6 mm, Phenomenex) with 2.0 mM aqueous CuSO4 as mobile 
phase at a flow rate of 1.2 mL/min, 20 °C, UV detection at 254 nm, tR = 29.8 min. The ee was 







































3. Screening of natural α-amino acids as substrates for EDDS lyase
General procedure: The initial reaction mixture (2.5 mL) consisted of fumaric acid 
(0.03 mmol) and a α-amino acid (see above, 0.3 mmol) in 20 mM NaH2PO4-NaOH buffer, 
and the pH of the reaction mixture was adjusted to pH 8.5. The enzymatic reaction was 
started by addition of freshly purified EDDS lyase (0.05 mol%) and the final volume of the 
reaction mixture was adjusted immediately to 3 mL with the same buffer. The reaction mix-
ture was incubated at room temperature for 48 h. The enzyme was inactivated by heating 
at 70 °C for 10 min. A sample (0.5 mL) was taken from the reaction mixture, filtered and 
the filtrate was evaporated under vacuum. The resulting residue was dissolved in 0.5 mL of 
D2O for 1H NMR measurement. The conversion was estimated by comparing the signals 
of substrates and corresponding product in 1H NMR spectra. No conversion was observed 
after 48 h for the α-amino acids given above in the EDDS lyase-catalyzed addition to fuma-
ric acid. 
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4. One-pot chemoenzymatic synthesis of AMB and related 
compounds
One-pot synthesis of (2S, 2’S)-2a (AMB) 
General procedure:
Step a: The reaction mixture consisted of (S)-2,3-diaminopropionoic acid hydrochlo-
ride (8a, 50 mg, 0.36 mmol), fumaric acid (124 mg, 1.1 mmol) and buffer (8 mL, 20 mM 
NaH2PO4/NaOH, pH=8.5), the pH was adjusted to pH 8.5. The reaction was started by 
addition of freshly purified EDDS lyase (0.05 mol%, 1.75 mL, 5.5 mg/mL), and the reaction 
mixture was incubated at room temperature for 24 h. The conversion (98%) was deter-
mined by 1H NMR, with integration of the respective substrate and product signals. 
Step b: Without purification of the enzymatic product, 2-bromoacetic acid (149 mg, 
1.07 mmol) and a catalytic amount of KI was added to the reaction mixture, followed by 
adjusting the pH to 11 by using NaOH (2 M). The reaction mixture was heated to 70 °C and 
stirred for 6 h; the pH was maintained at pH 11 by adding aqueous 2 M NaOH. The reaction 
mixture was applied to an anion exchange resin (acetate form, 10 g), which was pretreated 
with 1 M acetic acid (5 column volumes) and water (until pH was neutral). The column was 
washed with water (2 column volumes) and 1 M acetic acid (4 column volumes), salts and 
unreacted intermediate were removed. Product and access fumaric acid were eluted with 
1 M HCl (4 column volumes). The ninhydrin-positive fractions were collected and loaded 
onto a column packed with cation-exchange resin (10 g of Dowex 50W X8, 50-100 mesh), 
which was pretreated with 2 M aqueous ammonia (4 column volumes), 1 M HCl (2 column 
volumes) and water (4 column volumes). The column was washed with water (2 column 
volumes) to remove fumaric acid. The target product was eluted with 2 M aqueous ammo-
nia (4 column volumes). The ninhydrin-positive fractions were collected, concentrated 
under vacuum and lyophilized to provide the final product as ammonium salt. 
(2S)-N-{(2’S)-2-carboxy-2-[(carboxymethyl)amino]ethyl}aspartic acid (2S, 2’S)-2a (AMB)
White solid. 23 mg (2-step yield 23%). 1H NMR (500 MHz, 0.2 N 
NaOD/D2O): δ 3.37 (dd, J = 8.1, 5.6 Hz, 1H), 3.17 (d, J = 16.4 Hz, 
1H), 3.13 (dd, J = 7.7, 5.2 Hz, 1H), 3.08 (d, J = 16.3 Hz, 1H), 
2.68 (dd, J = 11.7, 5.2 Hz, 1H), 2.62 (dd, J = 11.7, 7.7 Hz, 1H), 2.50 (dd, J = 15.0, 5.6 Hz, 1H), 







































61.8, 51.05, 50.0, 41.5. HRMS (ESI+): calcd. for C9H15N2O8 [M+H]+: 279.0823, found: 
279.0821. Comparisons of 1H NMR and 2D 1H-1H COSY NMR spectra of (2S, 2’S)-3a with 
those of product 2a showed that the N-alkylation of 3a has unambiguously occurred at the 
2’-NH2 position (Figures S6-S9). 
One-pot synthesis of (2S, 2’S)-2b
The compound (2S, 2’S)-2b was prepared from (S)-2,3-diaminopropionoic acid hydrochlo-
ride (8a, 50 mg, 0.36 mmol), fumaric acid (124 mg, 1.1 mmol), 3-bromopropionic acid 
(138 mg, 0.90 mmol) and using EDDS lyase (0.05 mol%, 1.75 mL, 5.5 mg/mL) as the bio-
catalyst following the general procedure described above.
(2S)-N-{(2’S)-2-carboxy-2-[(carboxyethyl)amino]ethyl}aspartic acid (2S, 2’S)-2b
White solid. 10 mg (2-step yield 7%). 1H NMR (500 MHz, 
D2O): δ 4.06 (dd, J = 9.7, 4.5 Hz, 1H), 3.94 – 3.85 (m, 1H), 
3.63 (dd, J = 12.5, 4.5 Hz, 1H), 3.53 (t, J = 10.9 Hz, 1H), 3.35 (t, 
J = 6.5 Hz, 2H), 2.91 – 2.82 (m, 1H), 2.74 (dd, J = 17.6, 8.8 Hz, 
1H), 2.64 (t, J = 6.4 Hz, 2H); 13C NMR (126 MHz, D2O) δ 177.8, 177.0, 172.9, 170.2, 60.2, 
56.6, 44.4, 43.8, 35.4, 32.3. HRMS (ESI+): calcd. for C10H17N2O8 [M+H]+: 293.0979, found: 
293.0976.
One-pot synthesis of (2S, 3’S)-2c
The compound (2S, 3’S)-2c was prepared from (S)-2,4-diaminobutanoic acid hydrochloride 
(8c, 50 mg, 0.32 mmol), fumaric acid (113 mg, 0.97 mmol), 2-bromoacetic acid (138 mg, 
1.0 mmol) and using EDDS lyase (0.05 mol%, 1.55 mL, 5.5 mg/mL) as biocatalyst following 
the general procedure described above.
(2S)-N-{(3’S)-2-carboxy-3-[(carboxymethyl)amino]propyl}aspartic acid (2S, 2’S)-2c
White solid. 3.0 mg (2-step yield 3%).1H NMR (500 MHz, D2O): 
δ 3.84 (dd, J = 8.2, 3.9 Hz, 1H), 3.79 (dd, J = 8.1, 5.1 Hz, 1H), 
3.68 (d, J = 16.1 Hz, 1H), 3.62 (d, J = 16.2 Hz, 1H), 3.36 – 3.25 (m, 
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2H), 2.82 (dd, J = 17.6, 3.9 Hz, 1H), 2.70 (dd, J = 17.6, 8.2 Hz, 1H), 2.33 (ddt, J = 18.2, 14.8, 
7.7 Hz, 2H); 13C NMR (126 MHz, D2O): δ 176.6, 173.1, 172.1, 171.1, 59.6, 59.6, 48.1, 43.5, 
35.6, 26.2. HRMS (ESI+): calcd. for C10H17N2O8 [M+H]+: 293.0979, found: 293.0979.
5. Synthesis of precursors 
Synthesis of 9a-9c
(S)-3-amino-2-[(carboxymethyl)amino]propanoic acid (9a)
(S)-2-amino-3-[(tert-butoxycarbonyl)amino]propionic acid (S1, 163 mg, 
0.8 mmol) and bromoacetic acid (167 mg, 1.2 mmol) were dissolved in 
H2O (2 mL) and the pH of the reaction mixture was adjusted to 11 using 
aqueous NaOH (2 M). The reaction mixture was stirred at 70 °C for 6 h and the pH of the 
reaction mixture was maintained at pH 11 by frequent addition of aqueous NaOH (2 M). 
After completion of the reaction (monitored by 1H NMR), the solution was neutralized to 
pH 7 and subjected to lyophilization to provide the solid crude product S2. Compound 
S2 was directly used for the next step without purification. To a stirred solution of S2 in dry 
DCM (5 mL), in an ice-bath, was added trifluoroacetic acid (5 mL) dropwise. After the 
complete addition of trifluoroacetic acid, the ice-bath was removed and the reaction was 
allowed to proceed at room temperature for further 1.5 h. After completion of the starting 
material, solvent was removed in vacuo to provide crude product 9a, which was purified via 
anion exchange and cation exchange chromatography following a similar procedure to that 
used for 3a. White solid. 70 mg (2-step yield 54%). 1H NMR (500 MHz, D2O): δ 3.96 (dd, J 
= 7.7, 5.8 Hz, 1H), 3.78 (d, J = 16.3 Hz, 1H), 3.70 (d, J = 16.2 Hz, 1H), 3.53 (dd, J = 13.4, 
5.8 Hz, 1H), 3.48 (dd, J = 13.5, 7.8 Hz, 1H); 13C NMR (126 MHz, D2O): δ 171.4, 170.3, 57.7, 
48.5, 38.0. HRMS (ESI+): calcd. for C5H11N2O4 [M+H]+: 163.0713, found: 163.0715.
(S)-3-amino-2-[(2-carboxyethyl)amino]propanoic acid (9b)
To a stirred solution of (S)-2-amino-3-[(tert-butoxycarbonyl)amino] 
propionic acid (S1, 200 mg, 0.98 mmol) in 20 mM sodium phosphate 
buffer (10 mL, pH = 8.5) was added 3-bromopropionic acid (225 mg, 







































NaOH (2 M). The reaction mixture was heated to 50 °C and stirred for 12 h. The pH was 
maintained at 11 by frequent addition of aqueous NaOH (2 M). After completion of the 
reaction (monitored by 1H NMR), the solution was neutralized to pH 7 and subjected to 
lyophilization to provide the solid crude product S3. Compound S3 was directly used for 
the next step without purification. To a stirred solution of S3 in dry DCM (5 mL), in an ice-
bath, was added trifluoroacetic acid (5 mL) dropwise. After the complete addition of trif-
luoroacetic acid, the ice-bath was removed and the reaction was allowed to proceed at room 
temperature for further 1.5 h. After completion of the starting material, solvent was removed 
in vacuo to provide crude 9b, which was purified via cation exchange chromatography, 
followed by lyophilization. The resulting solid was precipitated in a mixture of H2O/MeOH/
AcOH (1.0 mL : 3.0 mL : 0.04 mL) to afford 9b as a white solid (70 mg, 2-step yield 41%). 
1H NMR (500 MHz, D2O) δ 3.93 (dd, J = 8.8, 5.0 Hz, 1H), 3.54 (dd, J = 13.3, 5.0 Hz, 1H), 
3.46 (dd, J = 13.2, 8.8 Hz, 1H), 3.31 (td, J = 6.5, 2.7 Hz, 2H), 2.61 (t, J = 6.5 Hz, 2H); 13C NMR 
(126 MHz, D2O) δ 178.0, 170.3, 57.2, 43.8, 37.6, 32.3. HRMS (ESI+): calcd. 
for C6H13N2O4 [M+H]+: 177.0875, found: 177.0871.
Methyl-(S)-4-[(tert-butoxycarbonyl)amino]-2-[(2-ethoxy-2-oxoethyl)amino]butanoate 
(S5)
To a stirred solution of methyl (S)-2-amino-4-[(tert-butoxycar bonyl)
amino]butanoate hydrochloride (S4, 100 mg, 0.37 mmol) in dry THF 
(5 mL) under nitrogen atmosphere was added Na2CO3 (102 mg, 
0.74 mmol) at room temperature. Later bromoethyl acetate (92 mg, 0.55 mmol) was added 
to the reaction mixture, and the reaction was run at 50 °C for 48 h. After completion of the 
reaction, the reaction mixture was diluted with water (5 mL) and extracted with EtOAc 
(20 mL x 3). The combined organic layers were washed with brine (50 mL), dried over 
Na2SO4 and evaporated to provide crude product S5, which was purified via flash column 
chromatography (EtOAc /Petroleum ether, 50%, v/v) to afford the desired pure product as 
colorless oil (110 mg, yield 93%). 1H NMR (500 MHz, CDCl3): δ 5.25 (s, 1H), 4.18 (q, J = 
7.1 Hz, 2H), 3.73 (s, 3H), 3.45 (d, J = 17.4 Hz, 1H), 3.35 – 3.25 (m, 4H), 1.97 – 1.90 (m, 1H), 
1.70 (ddt, J = 14.3, 8.6, 6.0 Hz, 2H), 1.44 (s, 9H), 1.27 (t, J = 7.2 Hz, 3H); 13C NMR (126 MHz, 
CDCl3): δ 174.9, 171.8, 156.0, 60.9, 59.0, 52.1, 49.1, 37.7, 32.8, 28.4 (3C), 14.2. HRMS (ESI+): 
calcd. for C14H27N2O6 [M+H]+: 319.1869, found: 319.1865.
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(S)-4-amino-2-[(carboxymethyl)amino]butanoic acid (9c)
To a stirred solution of S5 (100 mg, 0.31 mmol) in THF/H2O (1:1), in 
an ice-bath, was added LiOH (37 mg, 1.6 mmol). After 10 min, the 
cooling system was removed and the reaction mixture was stirred at 
room temperature for 3 h. After the completion of the reaction (1H NMR monitoring), the 
pH of the reaction mixture was adjusted to pH 7. The solvent was evaporated and the result-
ing solid S6 was dried overnight under high vacuum. Compound S6 was directly used for 
the next step without purification. To a stirred solution of S6 in dry DCM (5 mL) was added 
trifluoroacetic acid (3.0 mL) dropwise at 0 °C. After the complete addition of TFA, the reac-
tion was run at the same temperature for further 2 h. After completion of the reaction, 
solvent was evaporated and the product was purified by cation exchange chromatography 
followed by lyophilization to provide compound 9c (23 mg, 2-step yield 46%) as a white 
solid. 1H NMR (500 MHz, D2O): δ 3.66 (dd, J = 7.6, 5.7 Hz, 1H), 3.61 (d, J = 16.3 Hz, 1H), 
3.51 (d, J = 16.3 Hz, 1H), 3.24 – 3.11 (m, 2H), 2.18 (ddt, J = 18.1, 14.7, 7.6 Hz, 2H); 13C NMR 
(126 MHz, D2O): δ 173.9, 172.8, 60.0, 48.6, 36.7, 27.5. HRMS (ESI+): calcd. 
for C6H11N2O4 [M-H]-: 175.0719, found: 175.0723.
Synthesis of 9d and 9e
(S)-2-[(tert-butoxycarbonyl)amino]-3-{[(S)-3’-(tert-butoxycarbonyl)amino]-1’-meth-
oxy-1’-oxopropan-2’-yl}amino propanoic acid (S9)
To a stirred solution of (S)-methyl 2-amino-3-[(tert-butoxycar-
bonyl)amino]propanoate (S7, 218 mg, 1.0 mmol) in CH3CN/H2O 
(1:1, 5 mL) was added Boc-L-serine-β-lactone (S8, 280 mg, 
1.5 mmol).3 The reaction mixture was stirred at room temperature for 8 h. Solvent was 
removed in vacuo to provide crude S9, which was purified via flash column chromatogra-
phy (MeOH/DCM, 5%, v/v) to give pure S9 (220 mg, yield 54%) as a white solid. 1H NMR 
(500 MHz, Methanol-d4): δ 4.15 (t, J = 6.1 Hz, 1H), 3.76 (brs, 4H), 3.50 – 3.42 (m, 2H), 
3.13 (dd, J = 12.0, 6.6 Hz, 1H), 3.03 (dd, J = 11.4, 5.6 Hz, 1H), 1.44 (s, 9H), 1.42 (s, 9H); 13C 
NMR (126 MHz, CDCl3): δ 173.3, 168.8, 156.6, 156.3, 80.2, 79.8, 60.6, 53.4, 52.5, 50.4, 40.6, 








































(S)-2-amino-3-[(S)-2’-amino-1’-carboxyethyl]amino propanoic acid (9d)
To a stirred solution of S9 (202 mg, 0.5 mmol) in THF/H2O (1:1, 
3 mL), in an ice-bath, was added LiOH (24 mg, 1 mmol). After 10 min, 
the cooling system was removed and the reaction mixture was stirred 
at room temperature for 2 h. After completion of the starting material, 
the pH of the reaction mixture was adjusted to pH 7. Solvents were removed in vacuo and 
the resulting solid (S10) was dried under vacuum overnight. Compound S10 was directly 
used for the next step without purification. To a stirred solution of S10 in dry DCM (3 mL), 
in an ice-bath, was added trifluoroacetic acid (2 mL) dropwise. After the complete addition 
of trifluoroacetic acid, the ice-bath was removed and the reaction was allowed to proceed at 
room temperature for 1.5 h. After completion of the starting material, solvent was removed 
to provide crude 9d, which was purified via cation exchange chromatography followed by 
lyophilization to provide 9d (71 mg, 2-step yield 74%) as a white solid. 1H NMR (500 MHz, 
D2O): δ 3.80 (dd, J = 5.4, 4.1 Hz, 1H), 3.31 – 3.21 (m, 3H), 2.96 (dd, J = 12.8, 9.5 Hz, 1H), 
2.83 (dd, J = 13.5, 4.1 Hz, 1H); 13C NMR (126 MHz, D2O): δ 177.8, 173.5, 60.9, 54.7, 47.1, 
41.2. HRMS (ESI+): calcd. for C6H14N3O4 [M+H]+: 192.0979, found: 192.0980.
(S)-4-amino-2-{[(S)-2’-amino-2’-carboxyethyl]amino}butanoic acid (9e)
To a stirred solution of S11 (200 mg, 0.75 mmol) in dry THF 
(10.0 mL) was added Na2CO3 (152 mg, 1.1 mmol) under nitrogen 
atmosphere at room temperature. Later, Boc-L-serine-β-lactone 
(S8, 187 mg, 1.0 mmol) was added to the reaction mixture and the 
reaction was run at 40 °C for 36 h. After completion of the reaction, solvent was evaporated 
followed by reverse extraction by using EtOAc (10 mL) and H2O (10 mL) to remove unre-
acted amine and lactone. The water layer was evaporated and lyophilized to afford 
S12 (98 mg). Compound S12 was directly used for the next step without purification.
To a stirred solution of S12 (98 mg, 0.23 mmol) in THF/H2O (1:1) was added LiOH (22 mg, 
0.93 mmol) at 0 °C. After 10 min, the cooling system was removed and the reaction mix-
ture was stirred at room temperature for 2 h. After the completion of the reaction, solvent 
was evaporated and the product S13 was dried overnight under high vacuum. Compound 
S13 was directly used for the next step without purification. To a stirred solution of S13 in 
dry DCM (5 mL) was added trifluoroacetic acid (3 mL) dropwise at 0 °C. After the complete 
addition of trifluoroacetic acid, the ice-bath was removed and the reaction was allowed to 
proceed at room temperature for 1.5 h. After completion of the reaction, the solvent was 
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evaporated and the product was purified by cation exchange chromatography, followed by 
lyophilization to provide compound 9e (23 mg, 3-step yield 46%). 1H NMR (500 MHz, 
0.2 N NaOD/D2O): δ 2.97 (dd, J = 8.8, 4.1 Hz, 1H), 2.71 (dd, J = 8.2, 5.7 Hz, 1H), 2.34 (dd, 
J = 11.8, 4.2 Hz, 1H), 2.24 (t, J = 7.5 Hz, 2H), 2.17 (dd, J = 11.8, 8.9 Hz, 1H), 1.37 – 1.25 (m, 
2H); 13C NMR (126 MHz, D2O): δ 180.3, 173.2, 62.0, 54.6, 47.4, 37.5, 29.8. HRMS (ESI+): 
calcd. for C7H16N3O4 [M+H]+: 206.1141, found: 206.1134.
6. Enzymatic synthesis of AMB, AMA and related compounds
(2S)-N-{(2’S)-2-carboxy-2-[(carboxymethyl)amino]ethyl}aspartic acid (2a)
The reaction mixture consisted of fumaric acid (93 mg, 
0.8 mmol), 9a (32.5 mg, 0.2 mmol) and 5 mL of buffer (20 mM 
NaH2PO4/NaOH, pH 8.5), and the pH of the reaction mixture 
was adjusted to pH 8.5 by 1 M NaOH aqueous solution. The enzy-
matic reaction was started by addition of freshly purified EDDS lyase (0.05 mol%) and the 
final volume of the reaction mixture was adjusted immediately to 6 mL with the same 
buffer. The reaction mixture was incubated at room temperature for 24 h. After completion 
of the reaction, the enzyme was inactivated by heating to 70 °C for 10 min. The conversion 
(80%) was monitored by 1H NMR spectroscopy. The purification was conducted by two 
steps of ion-exchange chromatography following a procedure similar to that used for 
chemoenzymatically prepared 2a. Light yellow solid. 29 mg (yield 47%). 1H NMR (500 MHz, 
0.2 N NaOD/D2O): δ 3.34 (dd, J = 8.2, 5.6 Hz, 1H), 3.16 (d, J = 16.3 Hz, 1H), 3.11 (dd, J = 
7.7, 5.1 Hz, 1H), 3.06 (d, J = 16.3 Hz, 1H), 2.67 (dd, J = 11.7, 5.1 Hz, 1H), 2.59 (dd, J = 11.7, 
7.7 Hz, 1H), 2.48 (dd, J = 15.1, 5.6 Hz, 1H), 2.31 (dd, J = 15.1, 8.2 Hz, 1H); 13C NMR 
(126 MHz, D2O): δ 181.5, 180.6, 179.9, 179.1, 63.1, 61.7, 51.0, 50.0, 41.4. HRMS (ESI+): 
calcd. for C9H15N2O8 [M+H]+: 279.0823, found: 279.0821. The 1H NMR spectrum of the 
enzymatically produced 2a was matched to that of chemoenzymatically synthesized (2S, 
2’S)-2a, which indicated that the absolute configuration of the enzymatically produced 2a 
was also (2S, 2’S), with a newly formed (2S)-configured chiral center and de >98%.
(2S)-N-{(2’S)-2-carboxy-2-[(carboxyethyl)amino]ethyl}aspartic acid (2b)
The reaction mixture consisted of fumaric acid (52 mg, 
0.45 mmol), 9b (20 mg, 0.11 mmol) and 5 mL of buffer 







































was adjusted to pH 9.0 by 1 M NaOH aqueous solution. The enzymatic reaction was started 
by addition of freshly purified EDDS lyase (0.15 mol%) and the final volume of the reaction 
mixture was adjusted immediately to 6 mL with the same buffer. The reaction mixture was 
incubated at 37 °C for 48 h. After completion of the reaction, the enzyme was inactivated by 
heating to 70 °C for 10 min. The conversion (65%) was monitored by 1H NMR spectros-
copy. Product purification was conducted by two steps of ion-exchange chromatography 
following a procedure similar to that used for 2a, providing 2b as a white solid (15 mg, yield 
46%). 1H NMR (500 MHz, D2O): δ 4.02 (dd, J = 9.1, 4.8 Hz, 1H), 3.86 (dd, J = 9.1, 3.7 Hz, 
1H), 3.59 (dd, J = 12.6, 4.8 Hz, 1H), 3.49 (dd, J = 12.6, 9.2 Hz, 1H), 3.33 (t, J = 6.5 Hz, 2H), 
2.84 (dd, J = 17.5, 3.7 Hz, 1H), 2.70 (dd, J = 17.5, 9.1 Hz, 1H), 2.62 (t, J = 6.5 Hz, 2H); 13C 
NMR (126 MHz, D2O): δ 178.0, 177.2, 173.2, 170.4, 60.3, 60.1, 44.4, 43.8, 35.6, 32.4. HRMS 
(ESI+): calcd. for C10H17N2O8 [M+H]+: 293.0976, found: 293.0976. The 1H NMR spectrum 
of the enzymatically produced 2b was identical to that of chemoenzymatically synthesized 
(2S, 2’S)-2b, which indicated that the absolute configuration of the enzymatically produced 
2b was (2S, 2’S), with a newly formed (2S)-configured chiral center and de >98%. 
(2S)-N-{(3’S)-3-carboxy-3-[(carboxymethyl)amino]propyl}aspartic acid (2c)
The reaction mixture consisted of fumaric acid (52 mg, 
0.45 mmol), 9c (20 mg, 0.11 mmol) and 5 mL of buffer (50 mM 
Tris/HCl, pH 9.0), and the pH of the reaction mixture was 
adjusted to 9.0 by 1 M NaOH aqueous solution. The enzymatic reaction was started by 
addition of freshly purified EDDS lyase (0.15 mol%) and the final volume of the reaction 
mixture was adjusted immediately to 6 mL with the same buffer. The reaction mixture was 
incubated at 37 °C for 48 h. After completion of the reaction, the enzyme was inactivated by 
heating to 70 °C for 10 min. The conversion (65%) was monitored by 1H NMR spectros-
copy. Product purification was conducted by two steps of ion-exchange chromatography 
following a procedure similar to that used for 2a, providing 2c as a white solid (10 mg, yield 
31%). 1H NMR (500 MHz, D2O): δ 3.81 (dd, J = 8.0, 3.9 Hz, 1H), 3.75 (t, J = 6.3 Hz, 1H), 
3.62 (q, J = 16.2 Hz, 2H), 3.31 – 3.25 (m, 2H), 2.80 (dd, J = 17.6, 3.8 Hz, 1H), 2.68 (dd, J = 
17.6, 8.1 Hz, 1H), 2.34 – 2.23 (m, J = 7.7 Hz, 2H); 13C NMR (126 MHz, D2O): δ 177.2, 173.2, 
172.5, 171.5, 59.6, 59.5, 48.2, 43.6, 35.7, 26.3. HRMS (ESI+): calcd. for C10H17N2O8 [M+H]+: 
293.0979, found: 293.0979. The 1H NMR spectrum of the enzymatically produced 2c was 
identical to that of chemoenzymatically synthesized (2S, 3’S)-2c, which indicated that the 
absolute configuration of the enzymatically produced 2c was (2S, 3’S), with a newly formed 
(2S)-configured chiral center and de >98%. 
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(2S)-N-{(2’S)-2’-[(2’’S)-2’’-amino-2’’-carboxyethyl]amino-2’-carboxyethyl}aspartic acid 
(1a, aspergillomarasmine A, AMA)
The reaction mixture consisted of fumaric acid (46 mg, 
0.4 mmol), 9d (19 mg, 0.1 mmol) and 4 mL of buffer (50 mM 
NaHCO3/Na2CO3, pH 9.0), and the pH of the reaction mix-
ture was adjusted to pH 9.0 by 1 M NaOH aqueous solution. 
The enzymatic reaction was started by addition of freshly purified EDDS lyase (0.15 mol%) 
and the final volume of the reaction mixture was adjusted immediately to 6 mL with the 
same buffer. The reaction mixture was incubated at 37 °C for 48 h. After completion of the 
reaction, the enzyme was inactivated by heating to 70 °C for 10 min. The conversion (79%) 
was monitored by 1H NMR spectroscopy. The pH of reaction mixture was adjusted to pH 
7 using 1 M acetic acid  and applied to an anion exchange resin (acetate form, 10 g), which 
was pretreated with 1 M acetic acid (5 column volumes) and pure water (until pH was neu-
tral). The column was washed with water (4 column volumes) to remove the unreacted 
starting substrate (S)-2-amino-3-[(S)-2’-amino-1’-carboxyethyl]aminopropanoic acid 
(9d), the product and the fumaric acid were eluted with 1 M LiCl aqueous solution 
(4 column volumes). The ninhydrin-positive fractions were collected and loaded onto a 
column packed with cation-exchange resin (10 g of Dowex 50W X8, 50-100 mesh), which 
was pretreated with 2 M aqueous ammonia (4 column volumes), 1 M HCl (2 column vol-
umes) and water (4 column volumes). The column was washed with water (4 column vol-
umes) to remove fumaric acid and salts. The final product was eluted with 2 M aqueous 
ammonia (4 column volumes). The ninhydrin-positive fractions were collected and 
lyophilized to yield the 1a (AMA) as ammonium salt. White solid, 8 mg (yield 26%). 
1H NMR (500 MHz, 50 mM NaD2PO4/D2O, pD=7.0): δ 3.72 – 3.68 (m, 2H), 3.25 (dd, J = 
9.9, 4.2 Hz, 1H), 3.16 – 3.10 (m, 2H), 2.99 (dd, J = 13.0, 9.9 Hz, 1H), 2.71 (dd, J = 13.5, 
3.9 Hz, 1H), 2.66 (dd, J = 17.6, 3.7 Hz, 1H), 2.54 (dd, J = 17.6, 9.4 Hz, 1H); 13C NMR 
(126 MHz, D2O): δ 177.3, 177.2, 173.1, 173.0, 59.7, 59.3, 54.4, 47.9, 47.0, 35.6. HRMS (ESI+): 
calcd. for C10H18N3O8 [M+H]+: 308.1088, found: 308.1087. 
In order to compare 1H NMR data of product 1a with the reported data on natural (2S, 2’S, 
2’’S)-AMA4, 600 MHz 1H NMR of product 1a was recorded. 1H NMR (600 MHz, 50 mM 
NaD2PO4/D2O, pD=7.0): δ 3.77 – 3.73 (m, 2H), 3.31 (dd, J = 9.7, 4.3 Hz, 1H), 3.19 (td, J 
= 13.8, 13.2, 5.0 Hz, 2H), 3.05 (dd, J = 12.7, 9.9 Hz, 1H), 2.77 (dd, J = 13.5, 3.7 Hz, 1H), 
2.72 (dd, J = 17.6, 3.5 Hz, 1H), 2.60 (dd, J = 17.5, 9.3 Hz, 1H). Comparison of the 1H 
NMR data of enzymatically prepared 1a with that of natural (2S, 2’S, 2’’S)-AMA4 (Table S1) 
and synthetic (2R, 2’S, 2’’S)-AMA5 confirmed that the enzymatic product 1a had the (2S, 









































A small amount of cyclized (S, S, S)-anhydro-AMA was obtained during 
the purification of 1a. 1H NMR (500 MHz, D2O): δ 4.14 – 4.11 (m, 2H), 
3.77 (dd, J = 10.2, 4.5 Hz, 1H), 3.57 (dd, J = 6.9, 3.8 Hz, 1H), 3.35 (dd, J 
= 13.8, 5.4 Hz, 1H), 3.10 (dd, J = 14.6, 4.5 Hz, 1H), 2.93 (dd, J = 13.8, 
6.9 Hz, 1H), 2.70 (dd, J = 16.5, 6.9 Hz, 1H), 2.50 (dd, J = 16.5, 3.9 Hz, 
1H). The 1H NMR data matched with the reported data of (S, S, S)-anhydro-AMA.6 HRMS 
(ESI+): calcd. for C10H16N3O7 [M+H]+: 290.0983, found: 290.0978.
Table S1. 1H NMR data comparison of natural (2S, 2’S, 2’’S)-AMA4 and enzymatic (2S, 2’S, 2’’S)-AMA.
Natural (2S, 2’S, 2’’S)-AMA
(600 MHz)
Enzymatic (2S, 2’S, 2’’S)-AMA
(600 MHz)
3.75 (dd, J = 9.1, 3.6, 1H)
3.77 – 3.73 (m, 2H)
3.74 (dd, J = 5.7, 4.1, 1H)
3.35 (dd, J = 9.5, 4.5, 1H) 3.31 (dd, J = 9.7, 4.3 Hz, 1H)
3.21 (dd, J = 12.8, 4.5, 1H)
3.19 (td, J = 13.8, 13.2, 5.0 Hz, 2H)
3.19 (dd, J = 13.5, 5.7, 1H)
3.06 (dd, J = 12.8, 9.5, 1H) 3.05 (dd, J = 12.7, 9.9 Hz, 1H)
2.80 (dd, J = 13.5, 4.1, 1H) 2.77 (dd, J = 13.5, 3.7 Hz, 1H)
2.73 (dd, J = 17.9, 3.6, 1H) 2.72 (dd, J = 17.6, 3.5 Hz, 1H)
2.61 (dd, J = 17.9, 9.1 1H) 2.60 (dd, J = 17.5, 9.3 Hz, 1H)
(2S)-N-{(3’S)-3’-[(2’’S)-2’’-amino-2’’-carboxyethyl]amino-3’-carboxypropyl}aspartic acid 
(1b)
The reaction mixture consisted of fumaric acid (52 mg, 
0.45 mmol), 9e (20 mg, 0.11 mmol) and 5 mL of buffer (50 mM 
Tris/HCl, pH 9.0), and the pH of the reaction mixture was 
adjusted to pH 9.0 by 1 M NaOH aqueous solution. The enzy-
matic reaction was started by addition of freshly purified EDDS lyase (0.15 mol%) and the 
final volume of the reaction mixture was adjusted immediately to 6 mL with the same 
buffer. The reaction mixture was incubated at 37 °C for 48 h. After completion of the reac-
tion, the enzyme was inactivated by heating to 70 °C for 10 min. The conversion (65%) 
was monitored by 1H NMR spectroscopy. The reaction mixture was applied to an anion 
exchange resin (acetate form, 10 g), which was pretreated with 1 M acetic acid (5 column 
volumes) and pure water (until pH was neutral). The column was washed with water 
(2 column volumes) and the product was eluted with 1 M acetic acid (4 column volumes). 
The ninhydrin-positive fractions were collected and lyophilized. The resulting white solid 
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was precipitated in a mixture of H2O : MeOH : AcOH (1.0 mL : 3.0 mL : 0.04 mL) to afford 
1b (5 mg, yield 20%). 1H NMR (500 MHz, 0.2N NaOD/D2O): δ 3.02 – 2.96 (m, 2H), 2.69 (dd, 
J = 8.0, 5.7 Hz, 1H), 2.35 (dd, J = 11.8, 4.1 Hz, 1H), 2.18 – 2.09 (m, 4H), 1.97 (dd, J = 15.0, 
7.8 Hz, 1H), 1.46 – 1.39 (m, 1H), 1.34 – 1.26 (m, 1H); 13C NMR (126 MHz, 0.2N NaOD/
D2O): δ 181.7, 181.4, 181.4, 179.7, 62.1, 62.0, 61.1, 61.0, 55.6, 44.0. HRMS (ESI+): calcd. 
for C11H20N3O8 [M+H]+: 322.1250, found: 322.1242.




Compound S15 was synthesized according to a procedure published 
elsewhere.7 1H NMR (500 MHz, CDCl3): δ 5.41 (d, J = 8.4 Hz, 1H), 
4.41 (dt, J = 8.9, 4.7 Hz, 1H), 3.15 (dd, J = 16.3, 4.8 Hz, 1H), 3.03 (dd, J = 
16.3, 4.7 Hz, 1H), 2.96 – 2.82 (m, 2H), 1.45 (s, 9H), 1.43 (s, 9H), 1.24 (t, J = 7.4 Hz, 3H). 
The 1H NMR data of S15 matched with the reported data.7
tert-Butyl (S)-2-[(tert-butoxycarbonyl)amino]-4-oxobutanoate (S16)
Compound S16 was synthesized according to a procedure published else-
where.7 1H NMR (500 MHz, CDCl3): δ 9.73 (s, 1H), 5.36 (d, J = 7.0 Hz, 1H), 
4.52 – 4.42 (m, 1H), 2.98 (qd, J = 18.0, 4.9 Hz, 2H), 1.45 (s, 9H), 1.44 (s, 
9H). The 1H NMR data of S16 matched with the reported data.7
Di-tert-butyl {(S)-4-(tert-butoxy)-3-[(tert-butoxycarbonyl)amino]-4-oxobutyl}-L-aspar-
tate (S18)
To a stirred solution of di-tert-butyl L-aspartate (S17, 197 mg, 
0.80 mmol) and NaCNBH3 (58 mg, 0.91 mmol) in dry MeOH 
(5 mL) was added aldehyde S16 (200 mg, 0.73 mmol) at room 







































the reaction, solvent was evaporated and the crude product was purified by flash column 
chromatography (EtOAc/Petroleum ether, 20%, v/v) to afford the desired product S18 as 
colorless oil (140 mg, yield 38%). 1H NMR (500 MHz, CDCl3): δ 5.47 (d, J = 7.9 Hz, 1H), 
4.19 (q, J = 7.3 Hz, 1H), 3.41 (t, J = 6.4 Hz, 1H), 2.79 (dt, J = 12.2, 7.0 Hz, 1H), 2.60 – 2.51 (m, 
2H), 2.48 (dd, J = 15.9, 6.8 Hz, 1H), 1.95 – 1.82 (m, 2H), 1.82 – 1.70 (m, 1H), 1.44 (s, 9H), 
1.44 (s, 9H), 1.43 (s, 9H), 1.42 (s, 9H); 13C NMR (126 MHz, CDCl3): δ 172.9, 171.9, 170.3, 
155.6, 81.7, 81.6, 81.0, 79.6, 58.6, 52.9, 44.4, 39.3, 32.6, 28.5 (3C), 28.2 (3C), 28.2 (3C), 
28.1 (3C). HRMS (ESI+): calcd. for C25H47N2O8 [M+H]+: 503.3332, found: 503.3326.
(2S)-N-[(3’S)-3’-amino-3’-carboxypropyl]aspartic acid (S19)
To a stirred solution of starting material S18 (125 mg, 0.25 mmol) 
in dry DCM (5 mL), in ice bath, was added trifluoroacetic acid 
(5.0 mL) dropwise. After the complete addition of trifluoroacetic 
acid, the ice bath was removed and the reaction was run at the room temperature for 6 h. 
After the completion of reaction, solvent was evaporated and the crude product was puri-
fied by cation exchange chromatography followed by lyophilization to provide compound 
S19 as ammonium salt (50 mg, yield 86%). 1H NMR (500 MHz, D2O): δ 3.88 – 3.79 (m, 2H), 
3.35 – 3.20 (m, 2H), 2.82 (dd, J = 17.6, 3.8 Hz, 1H), 2.68 (dd, J = 17.6, 8.6 Hz, 1H), 2.37 – 
2.15 (m, 2H); 13C NMR (126 MHz, D2O): δ 176.2, 173.2, 172.8, 59.2, 52.5, 43.8, 35.2, 27.1. 
HRMS (ESI+): calcd. for C8H15N2O6 [M+H]+: 235.0930, found: 235.0925.
 
Reference compounds S22a-c were prepared as previously reported.1 Compound 
S21 (0.1 mmol) and maleic acid (S20, 23 mg, 0.2 mmol) were dissolved in H2O (1 mL) 
and the pH of the reaction mixture was adjusted to pH 6 by 1 M NaOH aqueous solution. 
The reaction mixture was stirred for 4 h at 70 °C. After cooling to room temperature, the 
reaction mixture was basified to pH 9 and applied to ion exchange chromatography, follow-
ing a procedure similar to that used for 3a.
(2S/R)-N-[(3’S)-3’-amino-3’-carboxypropyl]aspartic acid (S22a)
White solid. 5 mg (21% yield). 1H NMR (500 MHz, D2O): δ 3.90 – 
3.74 (m, 4H), 3.32 – 3.25 (m, 2H), 3.22 – 3.14 (m, 2H), 2.87 – 
2.70 (m, 4H), 2.35 – 2.20 (m, 4H). HRMS (ESI+): calcd. 
for C8H15O6N2 [M+H]+: 235.0925, found: 235.0918. 
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(2S/R)-N-[(4’S)-4’-amino-4’-carboxybutyl]aspartic acid (S22b)
White solid. 3 mg (12% yield). 1H NMR (500 MHz, D2O): δ 3.87 – 
3.71 (m, 4H), 3.16 – 3.09 (m, 2H), 3.05 – 3.02 (m, 2H), 2.87 – 
2.69 (m, 4H), 2.01 – 1.70 (m, 8H); HRMS (ESI+): calcd. 
for C9H17O6N2 [M+H]+: 249.1081, found: 249.1074. 
(2S/R)-N-[(5’S)-5’-amino-5’-carboxypentyl]aspartic acid (S22c)
White solid. 2 mg (8% yield). 1H NMR (500 MHz, D2O): δ 
3.84 – 3.69 (m, 4H), 3.14 – 3.00 (m, 2H), 3.01 (t, J = 7.4 Hz, 2H), 
2.85 – 2.66 (m, 4H), 2.01 – 1.83 (m, 4H), 1.80 – 1.68 (m, 4H), 
1.55 – 1.42 (m, 4H). HRMS (ESI+): calcd. for C10H19O6N2 [M+H]+: 263.1238, found: 263.1235. 
 
Reference compounds S-S24 and R-S24 were prepared as previously reported.2 (S)-aspartic 
acid S23 (40 mg, 0.3 mmol) and bromoacetic acid (42 mg, 0.3 mmol) were dissolved in H2O 
(2 mL) and the pH of the reaction mixture was adjusted to pH 11 by 1 M NaOH aqueous 
solution. The reaction mixture was stirred for 6 h at 70 °C and the pH of the reaction mix-
ture was maintained at pH 11 by frequent addition of 1 M NaOH aqueous solution. After 
cooling to room temperature, the reaction mixture was directly applied to ion exchange 
chromatography, following a procedure similar to that used for 3f.
(2S)-N-(carboxymethyl)aspartic acid (S-S24) 
White solid. 16 mg (28% yield). 1H NMR (500 MHz, D2O): δ 3.86 (dd, J 
= 7.1, 4.4 Hz, 1H), 3.70 (d, J = 16.2 Hz, 1H), 3.63 (d, J = 16.2 Hz, 1H), 
2.87 (dd, J = 17.7, 4.4 Hz, 1H), 2.80 (dd, J = 17.7, 7.2 Hz, 1H). 13C NMR 
(126 MHz, D2O): δ 176.5, 172.9, 171.4, 59.0, 48.2, 34.8. HRMS (ESI+): calcd. for C6H10O6N 
[M+H]+: 192.0503, found, 192.0502. Chiral HPLC conditions: Chirex 3126-D-penicil-
lamine column (250 mm x 4.6 mm, Phenomenex). Phase A: 2.0 mM CuSO4 aqueous solu-
tion, phase B: isopropanol, A/B = 95:5 (v/v). Flow rate 1.0 mL/min, 25 °C, UV detection at 
254 nm, tR (S-isomer) = 2.4 min.
(2R)-N-(carboxymethyl)aspartic acid (R-S24) 
The title compound was obtained by reacting (R)-aspartic acid (40 mg, 
0.3 mmol) with bromoacetic acid (42 mg, 0.3 mmol) following a proce-







































1H NMR (500 MHz, D2O): δ 3.85 (dd, J = 7.1, 4.4 Hz, 1H), 3.70 (d, J = 15.1 Hz, 1H), 3.63 (d, 
J = 16.1 Hz, 1H), 2.87 (dd, J = 17.7, 4.3 Hz, 1H), 2.80 (dd, J = 17.6, 7.2 Hz, 1H); 13C NMR 
(126 MHz, D2O): δ 176.6, 173.0, 171.5, 59.0, 48.2, 34.9. HRMS (ESI+): calcd. for C6H10O6N 
[M+H]+: 192.0503, found: 192.0502. Chiral HPLC conditions: Chirex 3126-D-penicil-
lamine column (250 mm x 4.6 mm, Phenomenex). Phase A: 2.0 mM CuSO4 aqueous solu-
tion, phase B: isopropanol, A/B = 95:5 (v/v). Flow rate 1.0 mL/min, 25 °C, UV detection at 
254 nm, tR (R-isomer) = 5.4 min.
 
Reference compounds S-S25 and R-S25 were prepared as previously reported.2 (S)-aspartic 
acid S23 (40 mg, 0.3 mmol) and 3-bromopropanoic acid (46 mg, 0.3 mmol) were dissolved 
in H2O (2 mL) and the pH of the reaction mixture was adjusted to pH 11 by 1 M NaOH 
aqueous solution. The reaction mixture was stirred for 4 h at 70 °C and the pH of the reac-
tion mixture was maintained at pH 11 by frequent addition of 1 M NaOH aqueous solu-
tion. After cooling to room temperature, the reaction mixture was directly applied to ion 
exchange chromatography, following a procedure similar to that used for 3g.
(2S)-N-(2’-carboxyethyl) aspartic acid (S-S25) 
White solid. 8 mg (yield 13%). 1H NMR (500 MHz, D2O): δ 3.81 (dd, 
J = 8.0, 4.0 Hz, 1H), 3.27 (t, J = 6.4 Hz, 2H), 2.85 (dd, J = 17.7, 4.0 Hz, 
1H), 2.76 (dd, J = 17.7, 8.0 Hz, 1H), 2.67 (t, J = 6.4 Hz, 2H); 13C NMR 
(126 MHz, D2O): δ 177.2, 176.5, 173.0, 59.2, 43.3, 35.0, 31.8. HRMS (ESI+): calcd. 
for C7H12O6N [M+H]+: 206.0659, found: 206.0658. [α]D20 = −11.3 (c 0.37, 0.1 N NH3/H2O). 
Chiral HPLC conditions: Chirex 3126-D-penicillamine column (250 mm x 4.6 mm, Phe-
nomenex) with 2.0 mM aqueous CuSO4 as mobile phase at a flow rate of 0.8 mL/min, 20 °C, 
UV detection at 254 nm, tR (S-isomer) = 8.0 min.
(2R)-N-(2’-carboxyethyl)aspartic acid (R-S25)
The title compound was obtained by reacting (R)-aspartic acid 
(40 mg, 0.3 mmol) with 3-bromopropanoic acid (46 mg, 0.3 mmol) 
following a procedure similar to that used for (S)-S25. White solid. 
6 mg (yield 10%). 1H NMR (500 MHz, D2O): δ 3.81 (dd, J = 8.0, 4.0 Hz, 1H), 3.26 (t, J = 
6.4 Hz, 2H), 2.85 (dd, J = 17.7, 4.0 Hz, 1H), 2.75 (dd, J = 17.7, 8.1 Hz, 1H), 2.66 (t, J = 6.4 Hz, 
2H); 13C NMR (126 MHz, D2O): δ 177.4, 176.6, 173.1, 59.3, 43.3, 35.1, 32.0. HRMS (ESI+): 
calcd. for C7H12O6N [M+H]+: 206.0659, found: 206.0657. [α]D20 = +12.0 (c 0.34, 0.1 N NH3/
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H2O). Chiral HPLC conditions: Chirex 3126-D-penicillamine column (250 mm x 4.6 mm, 
Phenomenex) with 2.0 mM aqueous CuSO4 as mobile phase at a flow rate of 0.8 mL/min, 
20 °C, UV detection at 254 nm, tR (R-isomer) = 9.4 min.
 
(2R/S)-N-(3’-carboxypropyl)aspartic acid (rac-S26)
Reference compound rac-S26 was prepared as previously 
reported.8 Maleic acid (S20, 116 mg, 1 mmol) and 4-aminobuta-
noic acid (103 mg, 1 mmol) were dissolved in H2O (5 mL). Satu-
rated Ca(OH)2 aqueous solution was added slowly to neutralize all acid groups and adjust 
the pH to about 12 as measured initially at room temperature. The reaction mixture was 
heated to reflux for 4 h. After completion of the reaction, excess of Na2CO3 was added and 
the reaction mixture was stirred for 15 min. The precipitated CaCO3 was filtered and the 
filtrate was purified via ion exchange chromatography, following a procedure similar to that 
used for 3h. White solid. 90 mg (yield 41%). 1H NMR (500 MHz, D2O) δ 3.78 (dd, J = 7.7, 
4.0 Hz, 1H), 3.08 – 2.05 (m, 2H), 2.78 (dd, J = 17.5, 4.2 Hz, 1H), 2.67 (dd, J = 17.4, 7.8 Hz, 
1H), 2.29 (t, J = 7.4 Hz, 2H), 1.92 (p, J = 7.4 Hz, 2H); 13C NMR (126 MHz, D2O) δ 181.1, 
177.2, 173.3, 59.3, 46.3, 35.5, 34.1, 22.5. HRMS (ESI+): calcd. for C8H14O6N [M+H]+: 
220.0816, found: 220.0814. Chiral HPLC conditions: Chirex 3126-D-penicillamine column 
(250 mm x 4.6 mm, Phenomenex) with 2.0 mM aqueous CuSO4 as mobile phase at a flow 









































Figure S2. Comparison of the 1H NMR spectra of (2S, 2’S)-3a and (2S, 2’R)-3b with 0.2 M NaOD/
D2O as the solvent.
Figure S3. 1H NMR data comparison of diastereomeric mixture (2S/R, 3’S)-S22a, enzymatic product 
(2S, 3’S)-3c and authentic standard (2S, 3’S)-S19.
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Figure S4. 1H NMR data comparison of diastereomeric mixture (2S/R, 4’S)-S22b and enzymatic 
product 3d. 








































Figure S6. 1H-1H COSY (0.2 N NaOD/D2O) of (2S, 2’S)-3a (toxin A).
Figure S7. 1H-1H COSY (0.2 N NaOD/D2O) of (2S, 2’S)-2a (AMB).
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Figure S8. HMQC (0.2 N NaOD/D2O) of (2S, 2’S)-2a.
Figure S9. Comparison of 1H NMR spectra of (2S, 2’S)-3a (toxin A) and (2S, 2’S)-2a (AMB) with 0.2 







































IV) Chiral HPLC analysis
Figure S10. Chiral HPLC analysis of product 3f.Chiral HPLC conditions: Chirex 3126-D-penicillamine 
column (250 mm x 4.6 mm, Phenomenex). Phase A: 2.0 mM CuSO4 aqueous solution, phase B: 
isopropanol, A/B = 95:5 (v/v). Flow rate 1.0 mL/min, 25 °C, UV detection at 254 nm. 
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Figure S11. Chiral HPLC analysis of product 3g.Chiral HPLC conditions: Chirex 3126-D-penicillamine 
column (250 mm x 4.6 mm, Phenomenex) with 2.0 mM aqueous CuSO4 as mobile phase at a fl ow rate 







































Figure S12. Chiral HPLC analysis of product 3h. Chiral HPLC conditions: Chirex 3126-D-penicillamine 
column (250 mm x 4.6 mm, Phenomenex) with 2.0 mM aqueous CuSO4 as mobile phase at a fl ow rate 
of 1.2 mL/min, 20 °C, UV detection at 254 nm. 
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